Journal article
Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
Abstract
The investigators evaluated the impact of recombinant human erythropoietin (r-HuEPO) therapy on health-related quality of life (HRQL) in predialysis chronic renal disease patients with anemia. Eighty-three patients were entered into a randomized, parallel-group, open-label clinical trial with follow-up evaluations over 48 weeks. Forty-three patients were assigned to r-HuEPO treatment, and 40 patients were assigned to an untreated control group. …
Authors
Revicki DA; Brown RE; Feeny DH; Henry D; Teehan BP; Rudnick MR; Benz RL
Journal
American Journal of Kidney Diseases, Vol. 25, No. 4, pp. 548–554
Publisher
Elsevier
Publication Date
April 1995
DOI
10.1016/0272-6386(95)90122-1
ISSN
0272-6386